Plus   Neg

Stock Alert: Zogenix Loses 14%

Shares of Zogenix, Inc. (ZGNX) are sinking more than 14% on Thursday morning after the pharmaceutical company developing rare disease therapies, said the FDA has extended the review period for the New Drug Application (NDA) for the company's drug candidate FINTEPLA.

The new Prescription Drug User Fee Act (PDUFA) target action date for FINTEPLA, for the treatment of seizures associated with Dravet syndrome, has been extended by three months to June 25, 2020.

ZGNX is currently trading at $22.47, close to its 52-week low of $18.27.

We had alerted about this stock on February 7, when it was trading at $37. The stock is nearly 40% down since then.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The European Commission said Friday that it has signed a deal with Sanofi and GlaxoSmithKline to secure up to 300 million doses of their potential COVID-19 vaccine. Acella Pharmaceuticals recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to super potency, the U.S. Food and Drug Administration said in a statement. The company is recalling one lot of 15mg and one lot of 120mg of NP Thyroid that are packaged in 100 count bottles in strengths of 15 mg, and 120 mg, with expiration dates between October 2020 and November 2020. Walmart announced its decision to raise wages for around 165,000 hourly associates across all its U.S. stores starting October, and introduce a team-based operating model in Supercenters. In a tweet, the retail giant said, "Today we're introducing new leadership roles and cross-training opportunities, giving our associates more ways to grow their careers."
Follow RTT